Abstract: A massage tool includes a rod having a proximal end and a distal end, and a body follower having a proximal side and a distal side. The proximal end is configured for attachment to a reciprocating shaft of a reciprocating motor. The reciprocating shaft has a stroke axis and a stroke length, and the distal end of the rod is configured to rotatably attach to the proximal side of the body follower by means of a rotating joint defining a center of rotation. The distal side of the body follower may include a body contact area having a maximum length at least three times greater than a minimum distance from the center of rotation of the rotating joint to the body contact area.

Abstract: A massage tool includes a rod having a proximal end and a distal end, and a body follower having a proximal side and a distal side. The proximal end is configured for attachment to a reciprocating shaft of a reciprocating motor. The reciprocating shaft has a stroke axis and a stroke length, and the distal end of the rod is configured to rotatably attach to the proximal side of the body follower by means of a rotating joint defining a center of rotation. The distal side of the body follower may include a body contact area having a maximum length at least three times greater than a minimum distance from the center of rotation of the rotating joint to the body contact area.

Abstract: A massage tool includes a rod having a proximal end and a distal end, and a body follower having a proximal side and a distal side. The proximal end is configured for attachment to a reciprocating shaft of a reciprocating motor. The reciprocating shaft has a stroke axis and a stroke length, and the distal end of the rod is configured to rotatably attach to the proximal side of the body follower by means of a rotating joint defining a center of rotation. The distal side of the body follower may include a body contact area having a maximum length at least three times greater than a minimum distance from the center of rotation of the rotating joint to the body contact area.

Abstract: The invention provides compounds of formula I: and salts and prodrugs thereof wherein R4, X1 and X2 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.

Abstract: The invention provides compounds of formula I: and salts and prodrugs thereof wherein R4, X1 and X2 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.

Abstract: The invention provides compounds of formula (I) and salts thereof wherein R4-R8 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.

Abstract: The invention provides compounds of formula I: and salts thereof wherein R1-R4 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts, and methods for their use in therapy. The compounds have useful antiviral properties.

Abstract: The invention provides compounds of formula (I): and salts and prodrugs thereof wherein R4, X1 and X2 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.

Abstract: The invention provides compounds of formula I: and salts thereof wherein R1-R4 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts, and methods for their use in therapy. The compounds have useful antiviral properties.

Abstract: The invention provides compounds of formula (I) and salts thereof wherein R4-R8 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.

Abstract: The invention provides compounds of formula (I): and salts and prodrugs thereof wherein R4, X1 and X2 have any of the meanings defined in the specification, as well as pharmaceutical compositions comprising the compounds or salts and methods for their use in therapy. The compounds have useful antiviral properties.

Abstract: The invention provides inhibitors of influenza endonuclease activity and tools for their discovery.

Abstract: The invention provides inhibitors of influenza endonuclease activity and tools for their discovery.

Abstract: A system and method for direct and immediate transmittal of voice messages is provided. A sender mobile device (MD) is capable of sending instant voice messages to at least one recipient MD over a wireless communications network. The recipient MD(s) are can store the instant voice message in a computer readable memory. The sender MD can query a database and/or the recipient MD(s) to determine if the recipient MD is compatible and/or subscribed to instant voice messaging service. If the recipient MD is compatible and/or subscribed, the voice message is sent directly to the recipient MD, stored, and an instant voice message waiting indicator is presented to the recipient. If the recipient MD is not compatible and/or subscribed, the voice message is sent directly to a voicemail server, stored, and a voice message waiting indicator is presented to the recipient.

Abstract: The invention provides a target and methods for specific binding and inhibition of RlmA proteins from bacterial specie The invention is directed to a method for identifying compounds that bind to a bacterial RlmA-binding pocket, comprising preparing a reaction solution comprising the compound to tested and an entity comprising a bacterial RlmA-binding pocket and detecting presence or amount of binding. The invention has applications in control of bacterial gene expression, control bacterial growth, antibacterial chemistry, and antibacterial therapy.

Abstract: The present invention provides an immunogenic composition comprising: (a) an isolated recombinant chimeric human rhinovirus, wherein the recombinant chimeric human rhinovirus comprises (i) a nucleic acid having a nucleotide sequence of a human rhinovirus encoding at least a portion of a human rhinovirus capsid; (ii) a heterologous nucleic acid having a nucleotide sequence encoding a chimeric region, wherein the chimeric region is expressed on the surface of the chimeric rhinovirus and is capable of participating in an immune reaction; and (iii)a pharmaceutically acceptable carrier.